Literature DB >> 9746785

Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.

G S Burgess1, E A Williamson, L D Cripe, S Litz-Jackson, J A Bhatt, K Stanley, M J Stewart, A S Kraft, H Nakshatri, H S Boswell.   

Abstract

Activity of the c-jun N-terminal kinase (JNK) has been shown in hematopoietic cells transformed by p210 BCR-ABL. However, analysis has not been reported for hematopoietic cells on the consequences of this activity for c-jun promoter regulation within its distinctive proximal 8-base consensus CRE-like element, an element linked to JNK-mediated increase in c-jun transcription. In the present study, regulation of the proximal c-jun promoter was studied in murine myeloid cells transformed by p210 BCR-ABL. Promoter regulation in p210 BCR-ABL transformed cells was compared with regulation of the promoter in nontransformed interleukin-3 (IL-3)-dependent parental cells. The composition of nuclear AP-1 proteins contained within cells with p210 BCR-ABL, and their binding to the c-jun promoter proximal CRE-like element, was compared with the composition and binding of AP-1 proteins in IL-3-treated parental cells without p210 BCR-ABL. The present analysis found fivefold increased c-jun transcription occurring in p210 BCR-ABL transformed murine myeloid cells possessing a corresponding magnitude of increased kinase activity of JNK, compared with IL-3-stimulated parental cells. Augmented JNK activity was accompanied by increased nuclear abundance of c-jun and c-fos proteins that bound specifically to the proximal c-jun promoter CRE element. Also, representative human leukemic cell lines expressing p210 BCR-ABL and possessing abundant kinase activity of JNK, when compared with parental cells that were deficient in JNK activity, had increased c-jun and c-fos proteins. Finally, to show the relevance of these observations in model systems, we studied blast cells from patients with Philadelphia chromosome-positive acute leukemic transformation, and observed comparable activities of JNK catalysis and c-jun/AP-1 protein relative to the cell lines that possessed p210 BCR-ABL and JNK activity. These studies provide a basis for investigating the set of downstream genes which augmented c-jun/AP-1 activity enlists in the process of transformation by p210 BCR-ABL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746785

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  The PEA-15 protein regulates autophagy via activation of JNK.

Authors:  Barbara C Böck; Katrin E Tagscherer; Anne Fassl; Anika Krämer; Ina Oehme; Hans-Walter Zentgraf; Martina Keith; Wilfried Roth
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

3.  Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization.

Authors:  Julia Schanda; Chun-Wei Lee; Katharina Wohlan; Uta Müller-Kuller; Hana Kunkel; Isabell Quagliano-Lo Coco; Stefan Stein; Alexander Metz; Joachim Koch; Jörn Lausen; Uwe Platzbecker; Hind Medyouf; Holger Gohlke; Michael Heuser; Matthias Eder; Manuel Grez; Michaela Scherr; Christian Wichmann
Journal:  Haematologica       Date:  2017-02-02       Impact factor: 9.941

4.  Elevated PIN1 expression by C/EBPalpha-p30 blocks C/EBPalpha-induced granulocytic differentiation through c-Jun in AML.

Authors:  J A Pulikkan; V Dengler; A A Peer Zada; A Kawasaki; M Geletu; Z Pasalic; S K Bohlander; A Ryo; D G Tenen; G Behre
Journal:  Leukemia       Date:  2010-04-08       Impact factor: 11.528

5.  Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.

Authors:  Yi-Chang Liu; Hui-Hua Hsiao; Jan-Gowth Chang; Ming-Yu Yang; Ta-Chih Liu; Chao-Song Chang; Shih-Bin Tseng; Huei-Jen Tsai; Sheng-Fung Lin
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

6.  BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.

Authors:  M Sattler; S Verma; C H Byrne; G Shrikhande; T Winkler; P A Algate; L R Rohrschneider; J D Griffin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

7.  Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.

Authors:  Kamaleldin E Elagib; Mang Xiao; Isa M Hussaini; Lorrie L Delehanty; Lisa A Palmer; Frederick K Racke; Michael J Birrer; Shanmugasundaram Ganapathy-Kanniappan; Ganapath Shanmugasundaram; Michael A McDevitt; Adam N Goldfarb
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival.

Authors:  Zhenyun Yang; Yiping Li; Fuqin Yin; Rebecca J Chan
Journal:  Exp Hematol       Date:  2008-07-21       Impact factor: 3.084

9.  Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.

Authors:  Zhenyun Yang; Takako Kondo; Cara S Voorhorst; Sarah C Nabinger; Leila Ndong; Fuqin Yin; Edward M Chan; Menggang Yu; Oliver Würstlin; Christian P Kratz; Charlotte M Niemeyer; Christian Flotho; Eri Hashino; Rebecca J Chan
Journal:  Mol Cell Biol       Date:  2009-06-15       Impact factor: 4.272

10.  Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.

Authors:  Jian feng Zhu; Zi jian Li; Guang sen Zhang; Kun Meng; Wen yong Kuang; Jin Li; Xin fu Zhou; Rui juan Li; Hong ling Peng; Chong wen Dai; Jian Kai Shen; Fan jie Gong; Yun xiao Xu; Su fang Liu
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.